دسترسی نامحدود
برای کاربرانی که ثبت نام کرده اند
دانلود کتاب Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy. A Handbook for Diagnosis and Management
دانلود کتاب بیماری های روماتیسمی و سندرم های ناشی از ایمونوتراپی سرطان. کتابچه راهنمای تشخیص و مدیریت
مشخصات کتاب
Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy. A Handbook for Diagnosis and Management
ویرایش: نویسندگان: Maria E. Suarez-Almazor, Leonard H. Calabrese (ed.) سری: ISBN (شابک) : 9783030568238, 9783030568245 ناشر: Springer سال نشر: 2021 تعداد صفحات: 361 زبان: English فرمت فایل : PDF (درصورت درخواست کاربر به PDF، EPUB یا AZW3 تبدیل می شود) حجم فایل: 6 مگابایت
قیمت کتاب (تومان) : 34,000
در صورت تبدیل فایل کتاب Rheumatic Diseases and Syndromes Induced by Cancer Immunotherapy. A Handbook for Diagnosis and Management به فرمت های PDF، EPUB، AZW3، MOBI و یا DJVU می توانید به پشتیبان اطلاع دهید تا فایل مورد نظر را تبدیل نمایند.
توجه داشته باشید کتاب بیماری های روماتیسمی و سندرم های ناشی از ایمونوتراپی سرطان. کتابچه راهنمای تشخیص و مدیریت نسخه زبان اصلی می باشد و کتاب ترجمه شده به فارسی نمی باشد. وبسایت اینترنشنال لایبرری ارائه دهنده کتاب های زبان اصلی می باشد و هیچ گونه کتاب ترجمه شده یا نوشته شده به فارسی را ارائه نمی دهد.
توضیحاتی درمورد کتاب به خارجی
فهرست مطالب
Introduction Contents Contributors Part I: Introduction Chapter 1: Cancer Immunology and the Evolution of Immunotherapy Cancer Immunology: Immunoediting Hypothesis Elimination Equilibrium Escape Cancer Immunotherapy Immune Checkpoint Inhibitors Cytokines Cancer Vaccines Adoptive Cell Therapy Epigenetic Drugs Future of Cancer Immunotherapy References Chapter 2: Cancer Immunotherapy: Overview of Immune Checkpoint Inhibitors CTLA-4 Inhibitors PD-1 and PD-L1 Inhibitors PD-1 Inhibitors Pembrolizumab Nivolumab Cemiplimab PDL-1 Inhibitors Atezolizumab Durvalumab Avelumab Combination Immunotherapy References Chapter 3: Immunopathogenesis of Immune-Related Adverse Events from Cancer Immunotherapy Autoimmunity or Autoinflammation? Putative Mechanisms of Immunopathogenesis Preclinical Models Lessons from Primary Immunodeficiency States Drugs and Disease Effects Basic Mechanisms of Autoimmunity and Autoinflammation for Checkpoint Inhibitors Experimental Construct for the Evolution of Autoimmune Diseases Proposed Immunologic Pathways Contributing to irAEs Generalized Immune Activation Direct Off-Target Effects of ICIs Preexisting Asymptomatic Autoimmunity Off-Target Effects of T Cell-Mediated Immunity Genetic and Environmental Factors Clinical Implications and Summary References Part II: Immune-Related Adverse Events with Immune-Checkpoint Inhibitors Chapter 4: Immune-Related Adverse Events with Immune Checkpoint Inhibitors: Arthritis Introduction Epidemiology Pathogenesis Clinical Manifestations Diagnosis Laboratory Testing Imaging Differential Diagnosis Management Immunosuppression and Tumor Response Prognosis Conclusions and Future Directions Case Study References Chapter 5: Immune-Related Adverse Events with Immune Checkpoint Inhibitors: Polymyalgia Rheumatica Introduction Epidemiology Pathogenesis Clinical Manifestations Diagnosis Differential Diagnosis Management Conclusions and Future Directions Case Study References Chapter 6: Myositis Introduction Epidemiology Pathogenesis Clinical Manifestations Diagnosis Differential Diagnosis Management Conclusions and Future Directions Case Study References Chapter 7: Sicca Syndromes Introduction Epidemiology Pathogenesis Histopathology Literature Review of Reported Cases Subsets of ICI-Induced Sicca De novo Development of Oral and/or Ocular Dryness Without Systemic Manifestations De Novo Development of Oral and/or Ocular Dryness with Systemic Manifestations Flare of a Recognized Preexisting Rheumatic Disease, Associated with Ocular and Oral Dryness Clinical Manifestations Diagnosis Differential Diagnosis Management ICI-Induced Sicca Without Systemic Symptoms ICI-Induced Sicca with Systemic Symptoms ICI-Induced Sicca in the Setting of Preexisting Rheumatic Disease Conclusions and Future Directions Case Study References Chapter 8: Sarcoidosis Introduction Epidemiology Pathogenesis Clinical Manifestations Diagnosis Differential Diagnosis Drug-Induced Pneumonitis Cancer Progression Infection Management Prognosis Conclusions and Future Directions Case Study References Chapter 9: Miscellaneous Rheumatic Syndromes Introduction Vasculitis Large Vessel Vasculitis Vasculitis of the Nervous System Other Vasculitides Systemic Lupus Erythematosus Scleroderma Eosinophilic Fasciitis Conclusions and Future Directions References Chapter 10: Non-Rheumatic Immune-Related Adverse Events Introduction Neurologic Immune-Related Adverse Events Acute Encephalitis Peripheral Neuropathy and Guillain-Barre Syndrome Myasthenia Gravis Ophthalmic irAEs: Uveitis Pulmonary irAEs: Pneumonitis Gastrointestinal irAEs Colitis Immune-Related Hepatitis Immune-Related Pancreatitis Hematologic irAEs: Immune-Related Thrombocytopenia Cardiovascular irAEs: Myocarditis and Pericarditis Dermatologic irAEs: Maculopapular Dermatitis and Pruritus Renal irAEs Endocrine irAEs: Hypophysitis, Hypothyroidism, and Type 1 Diabetes Mellitus Conclusions and Future Directions References Chapter 11: Immune-Related Adverse Events with Other Cancer Immunotherapies Adoptive Cell Therapies: Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Cytokine Release Syndrome Immune Effector Cell-Associated Neurotoxicity Syndrome Cytokines Recombinant Interferon-Alpha Recombinant Interleukin-2 Therapy Vascular Leak Syndrome Myocarditis Vaccines Sipuleucel-T Mycobacterium bovis Bacillus Calmette-Guérin (BCG) Conclusions and Future Directions References Part III: Cancer Immunotherapy in Patients with Pre-existing Rheumatic Diseases Chapter 12: Cancer Immunotherapy in Patients with Preexisting Inflammatory Arthritis Introduction Epidemiology Rheumatoid Arthritis Spondyloarthritis Pathogenesis Case Study Management References Chapter 13: Cancer Immunotherapy in Patients with Preexisting Rheumatic Diseases: Other Rheumatic Autoimmune Diseases Introduction Epidemiology Clinical Manifestations Diagnosis Management General Considerations Baseline Evaluation and Immunosuppressive Regimen Flare and/or irAE Management Conclusion Case Study References Part IV: General Principles of Management Chapter 14: Management of Rheumatic Immune-Related Adverse Events (irAEs): General Principles Introduction Guidelines ASCO/SITC Guidelines General Principles of Immunosuppression for Rheumatic irAEs: Targeted Therapies Anti-TNF-Directed Therapies Anti-IL-6-Directed Therapies Anti-IL-1-Directed Therapies Anti-IL-17-Directed Therapies Anti-B-Cell-Directed Therapies Janus Kinase Inhibitors (Jak-i) Abatacept Conclusions References Chapter 15: Benefit-Risk Considerations Evaluating the Potential Benefits and Risks of Therapies Benefits Types of Benefits Magnitude of Effect Duration Likelihood of Patients Experiencing a Benefit Medical Need Patient Values and Preferences Harms Types of Harms Severity and Impact Duration Likelihood of Risk Patient Tolerance of Risk and Uncertainty Multidisciplinary Approach Case Studies Conclusions and Future Directions References Chapter 16: Patient Education and Shared Decision-Making Patient Education Learning Needs Education Strategies Assessment of Health Literacy Patients’ Values Shared Decision-Making Forms of Health Communication Discredit False Information Discussing Immune-Related Adverse Events Management Plans Conclusions and Future Directions References Index
